2024
A confounder controlled machine learning approach: Group analysis and classification of schizophrenia and Alzheimer’s disease using resting-state functional network connectivity
Hassanzadeh R, Abrol A, Pearlson G, Turner J, Calhoun V. A confounder controlled machine learning approach: Group analysis and classification of schizophrenia and Alzheimer’s disease using resting-state functional network connectivity. PLOS ONE 2024, 19: e0293053. PMID: 38768123, PMCID: PMC11104643, DOI: 10.1371/journal.pone.0293053.Peer-Reviewed Original ResearchConceptsResting-state functional network connectivityFunctional network connectivityResting-state functional magnetic resonance imagingFunctional magnetic resonance imagingAlzheimer's diseaseClassification of schizophreniaNetwork pairsPatients to healthy controlsSchizophrenia patientsNeurobiological mechanismsSZ patientsSubcortical networksCerebellum networkSchizophreniaRs-fMRIDisorder developmentMotor networkCompare patient groupsSubcortical domainSZ disorderHealthy controlsMagnetic resonance imagingDisordersNetwork connectivityFunctional abnormalities
2023
Neuropsychiatric Disorder Subtyping Via Clustered Deep Learning Classifier Explanations *
Ellis C, Miller R, Calhoun V. Neuropsychiatric Disorder Subtyping Via Clustered Deep Learning Classifier Explanations *. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2023, 00: 1-4. PMID: 38083012, DOI: 10.1109/embc40787.2023.10340837.Peer-Reviewed Original ResearchConceptsDynamic functional network connectivityResting-state functional magnetic resonanceFunctional magnetic resonanceNeuropsychiatric disordersFunctional network connectivityCharacterization of schizophreniaCognitive controlDeep learning classifierContext of schizophreniaAuditory networkBrain activityBrain networksVisual networkSubcortical networksCerebellar network
2022
Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease
Hajjar I, Okafor M, Wan L, Yang Z, Nye J, Bohsali A, Shaw L, Levey A, Lah J, Calhoun V, Moore R, Goldstein F. Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease. Brain Communications 2022, 4: fcac270. PMID: 36440097, PMCID: PMC9683395, DOI: 10.1093/braincomms/fcac270.Peer-Reviewed Original ResearchProdromal Alzheimer's diseaseMild cognitive impairmentCognitive effectsCognitive functionCognitive impairmentNon-hypertensive individualsAlzheimer's diseasePositive cognitive effectsAssociated with improved executive functionComposite cognitive scoreGlobal cognitive functionFunctional network connectivityImproving global cognitive functionBrain amyloid accumulationExecutive functionExploratory outcomesCognitive measuresSubcortical networksHippocampal volumeNon-hypertensive adultsFalse discovery rate correctionParahippocampal regionIntention-to-treat approachPlacebo-controlled trialNon-hypertensive participants